Copyright Nasdaq. Minimum 15 minutes delayed.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.
Events & Presentations
|Summary Toggle Oct 2 - Oct 3, 2018||
Title: RX-3117, A NOVEL, ORAL NUCLEOSIDE ANALOG, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) IN FIRST-LINE METASTATIC PANCREATIC CANCER (MET-PC): SAFETY, TOLERABILITY AND PRELIMINARY RESPONSES [View Poster]
National Institutes of Health in Bethesda, Maryland
Sep 6, 2018
9:35 AM EDT Sep 6, 2018 9:35 AM EDT 09/06/18
|Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18||
Title: Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC) [View Poster]
Title: Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC) [View Poster]